全身2-[18F]FDG PET/CT低剂量优化:基于体重指数分层的单中心可行性研究
本研究纳入74例癌症患者,37例回顾性纳入全剂量组(3.7 MBq/kg),37例前瞻性纳入1/3剂量组(1.23 MBq/kg),1/3剂量组按BMI分层设定采集时间(BMI<25为5分钟,25≤BMI≤29为6分钟,BMI>29为8分钟)。结果显示1/3剂量组图像质量主观评分Likert评分均大于4分,与全剂量组在SUVmax、肝脏SUVmean及TBR上无显著差异,病灶检出率1/3剂量组93.24%(193/207)与全剂量组94.73%(198/209)无显著差异(p=0.520)。结论认为基于BMI分层的1/3剂量方案是临床可行的低剂量替代方案,病灶可检出性与全剂量方案等效。
要点
- 1/3剂量组按BMI分层采集:BMI<25为5分钟,25≤BMI≤29为6分钟,BMI>29为8分钟。
- 1/3剂量组主观Likert评分均大于4分,与全剂量组读者间一致性κ>0.88。
- 两组SUVmax、肝脏SUVmean及TBR无显著差异,病灶检出率无显著差异(p=0.520)。
核心结论
- 基于BMI分层的1/3剂量方案是临床可行的低剂量替代方案,病灶可检出性与全剂量方案等效,可能拓展个体化方案的应用。
研究设计与样本
- 单中心研究,74例癌症患者接受全身2-[18F]FDG PET/CT检查,37例回顾性纳入全剂量组(3.7 MBq/kg),37例前瞻性纳入1/3剂量组(1.23 MBq/kg)。
诊断标准与关键数值
- 1/3剂量组按BMI分层设定采集时间:BMI<25为5分钟(G5),25≤BMI≤29为6分钟(G6),BMI>29为8分钟(G8)。
- 主观评估1/3剂量与全剂量PET图像读者间一致性κ>0.88,1/3剂量组Likert评分大于4分。
- G5、G6、G8图像质量相当,G5病灶 conspicuity 高于G6和G8(p=0.045)。
- 客观评估1/3剂量组与全剂量组SUVmax、肝脏SUVmean及TBR无显著差异(p>0.05)。
- 病灶检出率1/3剂量组93.24%(193/207)与全剂量组94.73%(198/209)无显著差异(p=0.520)。
临床应用与阅片要点
- 基于BMI分层的1/3剂量方案可用于全身2-[18F]FDG PET/CT,图像质量临床可接受。
- 按BMI<25、25≤BMI≤29、BMI>29分别采用5、6、8分钟采集时间。
- G5方案病灶 conspicuity 高于G6和G8(p=0.045)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Implementing personalization protocol in clinical routine necessitates diverse low-dose PET/CT scan protocols. This study explores the clinical feasibility of one-third (1/3) dose regimen and evaluates the diagnostic image quality and lesion detectability of BMI-based 1/3-injection doses for 2-[18F]FDG PET/CT imaging.
METHODS: Seventy-four cancer patients underwent total-body 2-[18F]FDG PET/CT examination, with 37 retrospectively enrolled as full-dose group (3.7 MBq/kg) and 37 prospectively enrolled as the 1/3-dose group (1.23 MBq/kg). The 1/3-dose group was stratified by BMI, with an acquisition time of 5 min (G5), 6 min (G6), and 8 min (G8) for BMI < 25, 25 ≤ BMI ≤ 29, and BMI > 29, respectively. Image quality was subjectively and objectively assessed, and lesion detectability was quantitatively analyzed.
RESULTS: Subjective assessments of 1/3-dose and full-dose PET images showed strong agreement among readers (κ > 0.88). In the 1/3-dose group, the Likert scores were above 4. G5, G6, and G8 showed comparable image quality, with G5 demonstrating higher lesion conspicuity than G6 and G8 (p = 0.045). Objective evaluation showed no significant differences in SUVmax, liver SUVmean and TBR between 1/3- and full-dose groups (p > 0.05). No statistical differences were observed in the SUVmax of primary tumor, SUVmean of liver and TBR across all BMI categories between the 1/3-dose and full-dose groups. Lesion detection rates showed no significant difference between the 1/3-dose (93.24%, 193/207) and full-dose groups (94.73%, 198/209) (p = 0.520).
CONCLUSION: A BMI-stratified 1/3-dose regimen is a feasible low-dose alternative with clinically acceptable lesion detectability equivalent to full-dose protocol, potentially expanding the applicability of personalized protocols.
CLINICAL RELEVANCE STATEMENT: This study demonstrated that BMI-stratified 1/3-dose regimens for [18F]FDG total-body PET/CT yielded equivalent outputs compared to the full-dose regimen, which aligns with clinical needs for personalization in dose and BMI.
KEY POINTS: Currently, limited personalized low-dose total-body PET/CT protocols are available, particularly for patients with varied BMI. Reducing the radiotracer dose to 1/3 the standard demonstrated comparable image quality and lesion detectability equivalent to full dose. BMI-stratified 1/3-dose regimen is a clinically feasible low-dose alternative.
引用
- Gu T, Liu S, Hou X, et al. Low dose optimization for total-body 2-[18F]FDG PET/CT imaging: a single-center study on feasibility based on body mass index stratification. Eur Radiol. 2024. PMID: 39214892. doi:10.1007/s00330-024-11039-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。